![ASCO 2021: Addition of Palbociclib to Fulvestrant Attains Overall Survival Benefit in Advanced Breast Cancer With Update of PALOMA-3 | PracticeUpdate ASCO 2021: Addition of Palbociclib to Fulvestrant Attains Overall Survival Benefit in Advanced Breast Cancer With Update of PALOMA-3 | PracticeUpdate](https://d2ogjlfjkptkow.cloudfront.net/contentimage/30849.jpg)
ASCO 2021: Addition of Palbociclib to Fulvestrant Attains Overall Survival Benefit in Advanced Breast Cancer With Update of PALOMA-3 | PracticeUpdate
![Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice | Breast Cancer Research | Full Text Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice | Breast Cancer Research | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13058-021-01409-8/MediaObjects/13058_2021_1409_Fig1_HTML.png)
Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice | Breast Cancer Research | Full Text
![CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open—Cancer Horizons pro and con discussion - ESMO Open CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open—Cancer Horizons pro and con discussion - ESMO Open](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/eb1e420d-160c-4fc5-93c6-758949787e54/gr1.jpg)
CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open—Cancer Horizons pro and con discussion - ESMO Open
![Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis - The Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis - The](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/202eb2d7-8d5f-4a79-b730-6f9f23f8fec1/gr1_lrg.gif)
Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis - The
![Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial | Nature Medicine Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial | Nature Medicine](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-021-01562-9/MediaObjects/41591_2021_1562_Fig1_HTML.png)
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial | Nature Medicine
![Current Oncology | Free Full-Text | The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer | HTML Current Oncology | Free Full-Text | The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer | HTML](https://www.mdpi.com/curroncol/curroncol-29-00145/article_deploy/html/images/curroncol-29-00145-g004.png)
Current Oncology | Free Full-Text | The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer | HTML
![Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials | SpringerLink Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs10549-020-05782-4/MediaObjects/10549_2020_5782_Fig5_HTML.png)
Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials | SpringerLink
![Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER) - European Journal of Cancer Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER) - European Journal of Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/002895c2-2c29-4537-993c-0993908d313f/gr3_lrg.jpg)
Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER) - European Journal of Cancer
![Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) | SpringerLink Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs10549-020-05755-7/MediaObjects/10549_2020_5755_Fig2_HTML.png)
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) | SpringerLink
![Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/d1288ff9-0c7f-4332-b902-f99345f8a27e/figs1.jpg)
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology
![Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer - The Breast Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer - The Breast](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/f75c9398-32ab-4e2c-8ae3-fd666ba17b99/gr1_lrg.jpg)
Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer - The Breast
![Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer | Nature Communications Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-018-03215-x/MediaObjects/41467_2018_3215_Fig1_HTML.jpg)
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer | Nature Communications
![No Clear Survival Benefit for Fulvestrant Versus Letrozole in Combination With Palbociclib for Endocrine-Sensitive Metastatic Breast Cancer No Clear Survival Benefit for Fulvestrant Versus Letrozole in Combination With Palbociclib for Endocrine-Sensitive Metastatic Breast Cancer](https://dailynews.ascopubs.org/do/10.1200/ADN.20.200189/full/dn20_1007_figure.jpg)
No Clear Survival Benefit for Fulvestrant Versus Letrozole in Combination With Palbociclib for Endocrine-Sensitive Metastatic Breast Cancer
![Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/f4de198d-b2f2-4e80-b658-ce30b4b9918a/gr1.jpg)
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology
![Prognostic Factors for Overall Survival in Patients with Hormone Receptor‐Positive Advanced Breast Cancer: Analyses From PALOMA‐3 - Rugo - 2021 - The Oncologist - Wiley Online Library Prognostic Factors for Overall Survival in Patients with Hormone Receptor‐Positive Advanced Breast Cancer: Analyses From PALOMA‐3 - Rugo - 2021 - The Oncologist - Wiley Online Library](https://theoncologist.onlinelibrary.wiley.com/cms/asset/0dd777e2-21c3-4081-b448-ddb16db97ef5/onco13833-fig-0001-m.jpg)